Bruce L. Claflin - May 6, 2024 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role: Director
Signature: /s/ Lily J. Lu, Attorney-in-Fact for Bruce L. Claflin
Stock symbol: IDXX
Transactions as of: May 6, 2024
Transactions value $: $0
Form type: 4
Date filed: 5/8/2024, 07:00 PM
Previous filing: Mar 25, 2024
Next filing: May 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IDXX	Non-Qualified Stock Option (right-to-buy)	Award	$0	+609		$0.00	609	May 6, 2024	Common Stock	609	$476.87	Direct	F1
transaction	IDXX	Deferred Stock Unit	Award	$0	+262	+43.59%	$0.00	863	May 6, 2024	Common Stock	262		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.
F2	Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

Content

Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.